natgillin/translations-raw huggingface dataset:
Among children who were not already shedding virus at baseline, the incidence of laboratory-confirmed clinical influenza was reduced from 21 % (15 / 70) in the group not receiving prevention to 4 % (2 / 47) in the group receiving prevention (80.1 % reduction [95 % CI 22.0 – 94.9; p = 0.0206]).
V študiji se je incidenca klinične laboratorijsko potrjene influence pri otrocih, ki še niso imeli virusa na začetku, zmanjšala iz 21 % (15/70) v skupini, ki ni prejemala zdravila za preprečevanje, na 4 % (2/47) v skupini, ki je prejemala zdravilo za preprečevanje gripe (80,1-% zmanjšanje [95-% interval zaupanja 22,0 – 94,9; p=0,0206]).
Among co-infected patients in study 006, elevations in AST to greater than five times ULN developed in 13% of efavirenz-treated patients and in 7% of control, and elevations in ALT to greater than five times ULN developed in 20% and 7%, respectively.
Med sočasno okuženimi bolniki v študiji 006 je prišlo do zvišanj AST, večjih od petkratne ZMN, pri 13 % bolnikov, zdravljenih z efavirenzem, in pri 7 % bolnikov v kontrolni skupini, ter do zvišanj ALT, večjih od petkratne ZMN, pri 20 % bolnikov, zdravljenih z efavirenzem, ter pri 7 % bolnikov v kontrolni skupini.
Among co-infected patients, 3% of those treated with efavirenz and 2% in the control arm discontinued because of liverdisorders (see section 4.4).
Med sočasno okuženimi bolniki je 3 % tistih, ki so jemali efavirenz, in 2 % bolnikov iz kontrolnega kraka prekinilo zdravljenje zaradi bolezni jeter (glejte poglavje 4.4).
Among entecavir-treated nucleoside-naive patients, ALT elevations had a median time to onset of 23-
Pri bolnikih, ki so se zdravili z entekavirjem in se pred tem še niso zdravili z nukleozidi, je bil srednji čas do pojava povišanja vrednosti ALT 23 - 24 tednov.
Among genotype 1b/1other-infected subjects, the median age was 55 years (range: 22 to 82); 61% were male; 60 % were White; 20% were Black or African American; 6% were Hispanic or Latino; 82% were treatment-naïve subjects; 18% were treatment-experienced subjects; mean body mass index was 26 kg/m2; 64 % had baseline HCV RNA levels greater than 800,000 IU/mL; 22 % had cirrhosis; 71% had non-C/C IL28B alleles (CT or TT); 18 % had HCV/HIV-1 co-infection.
Med preiskovanci, okuženimi z genotipom 1b/drugimi genotipi 1, je bila mediana starost 55 let (v razponu od 22 do 82), 61 % je bilo moških, 60 % je bilo belcev, 20 % je bilo črncev ali Afroameričanov, 6 % je bilo Latinoameričanov, 82 % je bilo predhodno nezdravljenih, 18 % je bilo predhodno že zdravljenih, povprečni indeks telesne mase je bil 26 kg/m2, 64 % je imelo izhodiščno koncentracijo HCV RNA večjo kot 800.000 i.e./ml, 22 % je imelo cirozo, 71 % je imelo varianto IL28B ne-CC (CT ali TT), 18 % je imelo sočasno okužbo s HCV/HIV-1.
Among imatinib-intolerant patients, the estimated rate of PFS was 98% (95% CI: [95%-100%]) at 1 year and 94% (95% CI: [88%-99%]) at 2 years.
Pri bolnikih, ki imatiniba niso prenašali, je bil ocenjen delež preživetja brez progresije bolezni po 1 letu 98% (95% interval zaupanja: [95% - 100%]), po 2 letih pa 94% (95% interval zaupanja: [88% - 99%]).
Among imatinib-resistant patients, the estimated rate of PFS was 88% (95% CI: [84%-92%]) at 1 year and 75% (95% CI: [69%-81%]) at 2 years.
Pri na imatinib odpornih bolnikih je bil ocenjen delež preživetja brez progresije bolezni po 1 letu 88% (95% interval zaupanja: [84% - 92%]), po 2 letih pa 75% (95% interval zaupanja: [69% - 81%]).
Among lamivudine-refractory patients with baseline HBV DNA <107 log10 copies/ml, 64% (9/14) achieved HBV DNA <300 copies/ml at Week 48.
Pri bolnikih, neodzivnih na lamivudin, z izhodiščno vrednostjo HBV DNA <107 log10 kopij/ml je bila v 48. tednu pri 64% (9/14) dosežena vrednost HBV DNA <300 kopij/ml.
Among patients from study WV16240, who received Pegasys monotherapy and entered the long-term follow-up study, the rate of sustained HBeAg seroconversion 12 months after the end of therapy was 48% (73/153).
Med bolniki iz študije WV16240, ki so prejemali le zdravilo Pegasys in so bili vključeni v dolgotrajno študijo sledenja, je delež trajne HBeAg serokonverzije 12 mesecev po zaključkuzdravljenja znašal 48 % (73/153).
Among patients in the SBR arm who maintained their baseline regimen for 24 weeks and then switched to FTC/RPV/TDF, 92% (140/152) of patients had HIV-1 RNA < 50 copies/mL after 24 weeks of FTC/RPV/TDF, consistent with the Week 24 results for patients who switched to FTC/RPV/TDF at baseline.
Med bolniki v kraku z ohranitvijo začetnega režima, ki so 24 tednov ohranili svoj začetni režim in nato prešli na FTC/RPV/TDF, je imelo 92 % (140/152) bolnikov HIV-1 RNA < 50 kopij/ml po 24 tednih zdravljenja s FTC/RPV/TDF, kar je v skladu z rezultati za 24 tednov za bolnike, ki so na FTC/RPV/TDF prešli na začetku.
Among patients remaining in the study and treated Simponi, improvement of the SF-36 physical component was similar from week 104 through week 256.
Med bolniki, ki so ostali v študiji in so bili zdravljeni z zdravilom Simponi, so podobno izboljšanje rezultata vprašalnika SF-36 glede telesnega zdravja opažali od 104. do 256. tedna.
Among patients remaining in the study and treated with Simponi, DAS28 and HAQ DI responses were similar from week 104 through week 256.
Med bolniki, ki so ostali v študiji in so bili zdravljeni z zdravilom Simponi, so podobne stopnje odziva ACR (20/50/70) opažali od 104. do 256. tedna.
Among patients remaining in the study and treated with Simponi, improvement in HAQ DI was similar from week 104 through week 256.
Med bolniki, ki so ostali v študiji in so bili zdravljeni z zdravilom Simponi, so podobne vrednosti odzivov DAS 28 opažali od 104. do
Among patients remaining in the study and treated with Simponi, similar rates of ACR 20/50/70 response was observed from week 104 through week 256.
Med bolniki, ki so ostali v študiji in so bili zdravljeni z zdravilom Simponi, so podobne stopnje odziva ACR (20/50/70) opažali od 104. do 256. tedna.
Among patients remaining in the study and treated with Simponi, similar rates of patients showed no progression from baseline from week 104 through week 256.
Med bolniki, ki so ostali v študiji in so bili zdravljeni z zdravilom Simponi, so podobne radiografske učinke opažali od 104. do 256. tedna.
Among patients who achieved tumour reduction, the median time to maximum tumour reduction occurred in 5.6 and 5.5 months for laBCC and mBCC patients respectively, based on the IRF assessment.
Po oceni IRF je bila med bolniki, pri katerih je prišlo do zmanjšanja tumorja, mediana časa do največjega zmanjšanja tumorja 5,6 meseca za lokalno napredovali bazalnocelični karcinom in 5,5 meseca za metastatski bazalnocelični karcinom.
Among patients who had progressed on vemurafenib (n=66), the objective response rate was 15%.
Med bolniki, ki jim je bolezen med uporabo vemurafeniba napredovala (n = 66), je bil objektivni delež odziva 15 %.
Among patients who remained on the apremilast treatment to which they were randomized at study start, DAS28(CRP) score and PsARC response were maintained through Week 52.
Med bolniki, ki so ostali na zdravljenju z apremilastom, na katerega so bili randomizirani v začetku študije, sta odziva lestvice DAS28(CRP) in PsARC po 52 tednih še vedno trajala.
Among patients who remained on the apremilast treatment to which they were randomized at study start, these improvements were maintained through Week 52.
Med bolniki, ki so ostali na zdravljenju z apremilastom, na katerega so bili randomizirani v začetku študije, je to izboljšanje po 52 tednih še vedno trajalo.
Among patients who remained on the apremilast treatment, to which they were initially randomized at study start, improvement in physical function and FACIT- fatigue was maintained through Week 52.
Med bolniki, ki so ostali na zdravljenju z apremilastom, na katerega so bili randomizirani v začetku študije, se je izboljšanje telesnega delovanja in FACIT-utrujenosti ohranilo do vključno 52. tedna.
Among patients who remained on the Simponi treatment to which they were randomised at study start, improvement in HAQ DI was maintained through week 104.
Med bolniki, na začetku študije naključno razporejenimi v skupino, ki je prejemala zdravilo Simponi, so se pri tistih, ki so se še naprej zdravili z zdravilom Simponi, odzivi DAS 28 ohranili vse do 104. tedna.
Among patients who were at least partial responders at Week 12, and who received continuous weekly Humira therapy, the HiSCR rate at Week 48 was 64.3%.
Med bolniki, ki z vsaj delnim odzivom v 12. tednu, in ki so prejemali neprekinjeno tedensko terapijo Humira vsak teden, je bila stopnja kliničnega odziva (HiSCR) v 48. tednu bila 64,3%.
Among patients who were at least partial responders at Week 12, and who received continuous weekly Humira therapy, the HiSCR rate at Week 48 was 64.3%.
Pri bolnikih z vsaj delnim odzivom na zdravilo Humira v odmerku 40 mg v 12. tednu, in ki so prejemali neprekinjeno tedensko terapijo Humira vsak teden, je bila stopnja kliničnega odziva (HiSCR) v 48. tednu 64,3%.
Among patients who were evaluable for PD-L1 expression (98%), 82% were PD-L1 positive and 18% were PD-L1 negative.
Med bolniki, ki jih je bilo mogoče oceniti glede ekspresije PD-L1 (98 %), je bilo 82 % PD-L1 pozitivnih in 18 % PD-L1 negativnih.
Among patients who were initially randomized to apremilast 30 mg twice daily treatment, ACR 20/50/70 response rates were maintained through Week 52 in the pooled Studies PALACE 1, PALACE 2 and PALACE 3 (Figure 1).
Med bolniki, ki so bili v začetku randomizirani na zdravljenje z apremilastom 30 mg dvakrat na dan, so stopnje odzivnosti ACR 20/50/70 v združenih študijah PALACE 1, PALACE 2 in PALACE 3 trajale do 52. tedna (slika 1).
Among patients who were initially randomized to apremilast 30 mg twice daily treatment, the change from baseline in the HAQ-DI score at week 52 was -0.333 in the apremilast 30 mg twice daily group in a pooled analysis of the open label phase of studies PALACE 1, PALACE 2 and PALACE 3.
Pri bolnikih, ki so bili v začetku randomizirani na zdravljenje z apremilastom 30 mg dvakrat na dan, je bila v 52 tednu v združeni analizi odprte faze študij PALACE 1, PALACE 2 in PALACE 3 v skupini z apremilastom 30 mg dvakrat na dan sprememba rezultata HAQ-DI od izhodišča -0,333.
Among patients who were not in response at Week 4, 43% of Humira maintenance patients responded by Week 12 compared to 30% of placebo maintenance patients.
Med bolniki, ki so bili 4. teden brez odziva, se je do 12. tedna odzvalo 43 % tistih, ki so vzdrževalno dobivali zdravilo Humira, in 30 % tistih, ki so vzdrževalno dobivali placebo.
Among patients who were not in response at Week 4, 43% of Humira maintenance patients responded by week 12 compared to 30% of placebo maintenance patients.
Med bolniki, ki so bili 4. teden brez odziva, se je do 12. tedna odzvalo 43% tistih, ki so vzdrževalno dobivali zdravilo Humira, in 30 % tistih, ki so vzdrževalno dobivali placebo.
Among patients whose Humira treatment was withdrawn at Week 12 in Studies HS-I and HS-II, the HiSCR rate 12 weeks after re-introduction of Humira 40 mg weekly returned to levels similar to that observed before withdrawal (56.0 %).
Med bolniki, pri katerih je bilo zdravljenje z zdravilom Humira ukinjeno v 12. tednu v študijah HS-I in HS-II, se je po ponovni uvedbi zdravila Humira 40 mg enkrat na teden raven kliničnega odziva (HiSCR) vrnila na podobno raven, kot so jo opazili pred ukinitvijo (56,0%).
Among patients with diarrhoea, the median time to first event was 2 days (range, 1 to 594 days) and the median duration of any grade of diarrhoea was 2 days (range, 1 to 910 days).
Med bolniki z diarejo je bila mediana časa do prvega dogodka 2 dni (razpon 1 do 594 dni), mediana trajanja diareje katerekoli stopnje pa je bila 2 dni (razpon 1 do 910 dni).
Among patients with reports of adverse reactions of elevations in either ALT or AST (all grades), the median time of onset observed in the study was 28 days with a range of onset 6 to 841 days for ALT and 1 to 680 days for AST.
Pri bolnikih, pri katerih so poročali o neželenih učinkih povečanih vrednosti ALT ali AST (vse stopnje), je bila mediana časa do pojava, opažena v študiji, 28 dni, z razponom 6 do 841 dni za ALT ter 1 do 680 za AST.
Among patients with thrombocytopenia AEs, the median time to first event was 28 days (range, 1 to 968 days) and median duration per event was 14 days (range, 1 to 666 days).
Med osebami z neželenim učinkom trombocitopenijo je bila mediana časa do prvega dogodka 28 dni (razpon 1 do 968 dni), mediana trajanja dogodka pa je bila 14 dni (razpon 1 do 666 dni).
Among samples of oral mucosa, only 1 sample had detectable talimogene laherparepvec DNA during the study, but the sample did not test positive for presence of infective virus.
Med vzorci ustne sluznice je med študijo imel samo 1 vzorec detektirano DNA talimogena laherparepveka, vendar vzorec ni bil pozitiven za prisotnost infektivnega virusa.
Among the 1,618 dasatinib-treated patients with chronic phase CML, adverse reactions leading to discontinuation were reported in 329 (20.3%) patients, and among the 1,094 dasatinib-treated patients with advanced phase disease, adverse reactions leading to discontinuation were reported in 191 (17.5%) patients.
Od 1.618 bolnikov s KML v kroničnem obdobju je bilo zdravljenje z dasatinibom zaradi neželenih učinkov prekinjeno pri 329 (20,3%) bolnikih, od 1.094 bolnikov z boleznijo v napredovalem obdobju pa je bilo zdravljenje z dasatinibom zaradi neželenih učinkov prekinjeno pri 191 (17,5%) bolnikov.
Among the 11 BP CML patients, 3 patients remained on treatment for more than 24 weeks with notable responses (2 patients with a CCyR and 1 patient with a MaHR) and a treatment duration ranging from 46 to 118 weeks with one patient still on treatment.
Od 11 bolnikov s KML v blastni fazi so 3 bolniki ostali na zdravljenju več kot 24 tednov s pomembnimi odzivi (2 bolnika s CCyR in 1 bolnik s MaHR); trajanje zdravljenja je znašalo od 46 do 118 tednov, 1 bolnik še vedno ostaja na zdravljenju.
Among the 11 subjects, 2 developed the emtricitabine-associated resistance substitution M184V.
Od 11 bolnikov sta dva razvila z emtricitabinom povezano rezistenčno substitucijo M184V.
Among the 122 subjects with measurable lymph nodes at both baseline and post-baseline, 67 subjects (54.9%) achieved a ≥ 50% decrease from baseline in the sum of the products of the diameters (SPD) of index lesions.
Med 122 osebami z merljivimi bezgavkami ob izhodišču in po izhodišču je 67 oseb (54,9 %) doseglo ≥ 50-odstotno zmanjšanje od izhodišča glede na vsoto zmnožkov premerov (SPD) indikacijskih lezij.
Among the 1226 randomised patients, 89.4% and 90.2% of patients treated with the placebo/FOLFIRI and ZALTRAP/FOLFIRI regimens, respectively, received prior oxaliplatin-based combination chemotherapy in the metastatic/advanced setting.
Od 1226 randomiziranih bolnikov je predhodno kombinirano zdravljenje na podlagi oksaliplatina pri metastatskem/napredovalem raku dobivalo 89,4 % prejemnikov sheme placebo/FOLFIRI in 90,2 % prejemnikov sheme ZALTRAP/FOLFIRI.
Among the 19 patients,
Pri 1 od
Among the 300 (221 patients in the phase III part of the study and 79 patients in the phase II part) patients treated with docetaxel in combination with cisplatin and 5-fluorouracil in the gastric cancer study, 74 were 65 years of age or older and 4 patients were 75 years of age or older.
Med 300 bolniki (221 bolnikov v III. fazi študije in 79 bolnikov v II. fazi študije), ki so jih zdravili z docetakselom v kombinaciji s cisplatinom in 5-fluorouracilom v študiji raka želodca, je bilo 74 bolnikov starih 65 let ali več, 4 pa so bili stari 75 let ali več.
Among the 300 (221 patients in the phase III part of the study and 79 patients in the phase II part) patients treated with docetaxel in combination with cisplatin and 5-fluorouracil in the gastric cancer study, 74 were 65 years of age or older and 4 patients were 75 years of age or older.
Med 300 bolniki (221 bolnikov v III. fazi študije in 79 bolnikov v II. fazi študije), ki so se zdravili z docetakselom v kombinaciji s cisplatinom in 5-fluorouracilom v študiji raka ţelodca, je bilo bolnikov starih 65 let ali več, 4 pa so bili stari 75 let ali več.
Among the 300 (221 patients in the phase III part of the study and 79 patients in the phase II part) patients treated with docetaxel in combination with cisplatin and 5-fluorouracil in the gastric cancer study, 74 were 65 years of age or older and 4 patients were 75 years of age or older.
Med 300 bolniki (221 bolnikov v III. fazi študije in 79 bolnikov v II. fazi študije), ki so se zdravili z docetakselom v kombinaciji s cisplatinom in 5-fluorouracilom v študiji raka želodca, je bilo 74 bolnikov starih 65 let ali več, 4 pa so bili stari 75 let ali več.
Among the 314 subjects, 230 were infected with genotype 1a HCV and 84 were infected with genotype 1b HCV.
Med 314 preiskovanci je bilo 230 okuženih s HCV genotipa 1a in 84 s HCV genotipa 1b.
Among the 37 surgeries that occurred during the study, of which 12 were major, in only one case the blood loss was more than expected.
Med 37 kirurškimi posegi, od katerih jih je 12 bilo večjih, je samo eden bil takšen, da je prišlo do večje izgube krvi od pričakovane.
Among the 681 patients with diarrhoea, 104 patients (15%) were managed with treatment interruption and of these 98 (94%) were rechallenged with bosutinib.
Med 681 bolniki z diarejo je bilo pri 104 (15 %) bolnikih zdravljenje prekinjeno; od teh jih je 98 (94 %) ponovno začelo jemati bosutinib.
Among the children aged from 9 months to 2 years plasma concentrations of retapamulin were measurable in 32% (16/50) of samples.
Pri otrocih v starosti od 9 mesecev do 2 let je bila koncentracija retapamulina v plazmi merljiva v 32 % vzorcev (16/50).
Among the children who tested positive for antibodies to golimumab, 39% (25/69) had neutralising antibodies.
Med otroki, ki so bili pozitivni na protitelesa proti golimumabu, jih je imelo 39 % (25/69) nevtralizirajoča protitelesa.
Among the metabolites, 9.5% to 9.7% of the administered tegafur was excreted in the urine as 5-FU and approximately 70% to 77% as FBAL, accounting for approximately 83% to 91% of the administered Teysuno dose (total tegafur + 5-FU + FBAL).
Med presnovki se je 9,5–9,7 % prejetega tegafurja izločilo z urinom kot 5-FU in približno 70–77 % kot FBAL, kar ustreza približno 83–91 % prejetega odmerka zdravila Teysuno (skupno tegafur + 5-FU + FBAL).
Among the most frequent adverse reactions (at least in 2% of patients) in clinical studies in liver transplant patients receiving Envarsus were tremor, headache, fatigue, hyperkalaemia, hypertension, renal failure, blood creatinine increased, dizziness, hepatitis C, muscle spasms, tinea infection, leukopenia, sinusitis , and URTI, all of which are known to occur in the respective patient population under immunosuppressive treatment.
V kliničnih študijah pri bolnikih s presaditvijo jeter, ki so jemali zdravilo Envarsus, so bili najpogosteje poročani neželeni učinki (pojavili so se pri vsaj 2 % bolnikov) tremor, glabovol, utrujenost, hiperkaliemija, hipertenzija, odpoved ledvic, zvišanje kreatinina v krvi, omotica, hepatitis C, mišični spazmi, okužba s tineo, levkopenija, sinusitis in URTI, za katere je znano, da se pri imunosupresivnem zdravljenju pojavljajo pri zadevni populaciji bolnikov.
Among the patients included in the primary efficacy analysis, 139 patients had a current co-morbid diagnosis of ADHD.
Izmed bolnikov, ki so bili vključeni v primarno analizo učinkovitosti, je imelo 139 bolnikov sočasno tudi diagnozo motnje pomanjkanja pozornosti s hiperaktivnostjo (ADHD - Attention deficit hyperactivity disorder).
Among the patients treated with nivolumab in combination with ipilimumab in CA209067, 151/313 (48%) had the first onset of Grade 3 or 4 adverse reactions during the initial combination phase.
Pri bolnikih, ki so se v študiji CA209067 zdravili z nivolumabom v kombinaciji z ipilimumabom, so se med uvodno fazo kombiniranega zdravljenja neželeni učinki stopnje 3 ali 4 prvič pojavili pri 151/313 bolnikov (48 %).
Among the patients who received treatment with Epclusa + RBV for 12 weeks, 29% (25/85) of patients had baseline virus with NS5A RAVs: 29% (19/66), 75% (3/4), 15% (2/13), and 50% (1/2) for patients with genotype 1, 2, 3 and 4 HCV, respectively.
Od bolnikov, ki so prejemali zdravljenje z zdravilom Epclusa + RBV 12 tednov, je imelo 29 % (25/85) bolnikov izhodiščni virus z RAV NS5A: 29 % (19/66) bolnikov s HCV genotipa 1, 75 % (3/4) bolnikov s HCV genotipa 2, 15 % (2/13) bolnikov s HCV genotipa 3 in 50 % (1/2) bolnikov s HCV genotipa 4.
Among the patients who took Tarceva, the average survival was 8.6 months in those whose tumours were ‘EGFR IHC-positive’ (had EGFRs on their surface), and 5.0 months in those whose tumours were EGFR IHC-negative.
Pri bolnikih, ki so jemali zdravilo Tarceva, je bil povprečni čas preživetja 8,6 meseca pri tistih s tumorji z „EGFR, pozitivnim za IHC,“ (na svoji površini so imeli EGFR) in 5,0 meseca pri tistih s tumorji z „EGFR, negativnim za IHC“.
Among the patients with lymphoma, 60% of those receiving Mozobil achieved the target number of stems cells within four collection days (89 out of 150), compared with 20% of the patients receiving placebo (29 out of 148).
Med bolniki z limfomom je bilo pri 60 % tistih, ki so prejemali zdravilo Mozobil, doseženo ciljno število matičnih celic v štirih zbiralnih dnevih (89 od 150) v primerjavi z 20 % bolnikov, ki so prejemali placebo (29 od 148).
Among the patients with multiple myeloma, 72% of those receiving Mozobil achieved the target number of stem cells (106 out of 148), compared with 34% of the patients receiving placebo (53 out of 154).
Med bolniki z multiplim mielomom je bilo pri 72 % tistih, ki so prejemali zdravilo Mozobil, doseženo ciljno število matičnih celic (106 od 148) v primerjavi s 34 % bolnikov, ki so prejemali placebo (53 od 154).
Among the patients, 59 had autopsies carried out on them to prove conclusively whether or not they had significant amounts of β-amyloid plaques in their brains.
Pri bolnikih je bilo opravljenih 59 obdukcij, ki so dokončno potrdile, ali so imeli večje količine β- amiloidnih leh v možganih.
Among the subgroup of patients dose adjusted to 150 mg Q2W at week 12, an additional 25.4% reduction in LDL-C was achieved at week 24.
V podskupini bolnikov, ki so jim 12. teden odmerek prilagodili na 150 mg na 2 tedna, je bilo 24. teden doseženo dodatno 25,4 % znižanje LDL-H.
Among the subgroup of patients dose adjusted to 150 mg Q2W at week 12, an additional 7.3% mean reduction in LDL-C was achieved at week 24.
Podskupina bolnikov, ki so jim 12. teden odmerek prilagodili na 150 mg na 2 tedna, je do 24. tedna dosegla dodatno povprečno znižanje LDL-H za 7,3 %.
Among the subgroup of patients up-titrated at week 12, an additional 1.4 % mean reduction in LDL-C was achieved at week 24.
V podskupini bolnikov s povečanjem odmerka 12. teden je bilo do 24. tedna doseženo dodatno 1,4 % povprečno znižanje LDL-H.
Among the subgroup of patients up-titrated at week 12, an additional 10.5% mean reduction in LDL-C was achieved at week 24.
V podskupini bolnikov s povečanjem odmerka 12. teden je bilo do 24. tedna doseženo dodatno 10,5 % povprečno znižanje LDL-H.
Among the subgroup of patients up-titrated at week 12, an additional 15.7% mean reduction in LDL-C was achieved at week 24.
V podskupini bolnikov s povečanjem odmerka 12. teden je bilo do 24. tedna doseženo dodatno 15,7 % povprečno znižanje LDL-H.
Among the subgroup of patients up-titrated at week 12, an additional 22.8% mean reduction in LDL-C was achieved at week 24.
V podskupini bolnikov s povečanjem odmerka 12. teden je bilo do 24. tedna doseženo dodatno 22,8 % povprečno znižanje LDL-H.
Among the subjects who received placebo during the double-blind period, the proportion of subjects with HBV DNA < 400 copies/mL rose sharply after they began treatment with open-label TDF (PLB- TDF group): 74.1% (40/54) of subjects in the
Med bolniki, ki so v dvojno slepem obdobju prejemali placebo, je delež bolnikov s koncentracijo HBV DNA < 400 kopij/ml po začetku odprtega zdravljenja z TDF (skupina PLB–TDF) strmo narasel: v 192. tednu je 74,1% (40/54) bolnikov v skupini PLB–TDF imelo koncentracijo